Literature DB >> 159314

Suppression of immune complex vasculitis in rats by prostaglandin.

S L Kunkel, R S Thrall, R G Kunkel, J R McCormick, P A Ward, R B Zurier.   

Abstract

Immune complex-induced vascular damage can be markedly suppressed by treatment of rats with either prostaglandin (PG)E1 or its stable derivative, 15-(S)-15-methyl PGE1, but not with PGF2 alpha. In addition, PGD2 and PGE2 also show suppressive effects. The PGE1 derivative is considerably more effective than PGE1 and shows potent anti-inflammatory activity even after oral administration. Suppression of the vasculitis reaction is reflected by a greatly diminished increase in vasopermeability, indicating little or no vascular damage. In suppressed animals, the infiltration of neutrophils is greatly reduced, and those leukocytes that have appeared at tissue sites fail to show phagocytic uptake of immune complexes. In suppressed animals, the skin sites nevertheless show deposits of immune complexes and C3 fixation in vascular walls. Neutrophils harvested from the blood of rats treated with PGE1 show depressed responsiveness in chemotaxis and in enzyme secretion after incubation with chemotactic peptide. These studies indicate that certain PG have potent anti-inflammatory activity, which may be related to their effects on leukocytes.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 159314      PMCID: PMC371302          DOI: 10.1172/JCI109611

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  15 in total

1.  The mechanism of Arthus reactions. II. The role of polymorphonuclear leucocytes and platelets in reversed passive reactions in the guinea-pig.

Authors:  J H HUMPHREY
Journal:  Br J Exp Pathol       Date:  1955-06

2.  15-hydroxyprostaglandin dehydrogenase. A review.

Authors:  H S Hansen
Journal:  Prostaglandins       Date:  1976-10

3.  The role of cyclic 3',5' adenosine monophosphate in the specific cytolytic activity of lymphocytes.

Authors:  C S Henney; H R Bourne; L M Lichtenstein
Journal:  J Immunol       Date:  1972-06       Impact factor: 5.422

Review 4.  Immunologic tissue injury mediated by neutrophilic leukocytes.

Authors:  C G Cochrane
Journal:  Adv Immunol       Date:  1968       Impact factor: 3.543

5.  The immediate allergic response: in vitro action of cyclic AMP-active and other drugs on the two stages of histamine release.

Authors:  L M Lichtenstein; R DeBernardo
Journal:  J Immunol       Date:  1971-10       Impact factor: 5.422

6.  Immunological release of histamine and slow-reacting substance of anaphylaxis from human lung. I. Modulation by agents influencing cellular levels of cyclic 3',5'-adenosine monophosphate.

Authors:  R P Orange; W G Austen; K F Austen
Journal:  J Exp Med       Date:  1971-09-01       Impact factor: 14.307

7.  Combination of theophylline and prostaglandin E1 as inhibitors of the adjuvant-induced arthritis syndrome of rats.

Authors:  I L Bonta; M J Parnham; L Van Vliet
Journal:  Ann Rheum Dis       Date:  1978-06       Impact factor: 19.103

8.  Acute immunologic pulmonary alveolitis.

Authors:  K J Johnson; P A Ward
Journal:  J Clin Invest       Date:  1974-08       Impact factor: 14.808

9.  The structure-activity relations of synthetic peptides as chemotactic factors and inducers of lysosomal secretion for neutrophils.

Authors:  H J Showell; R J Freer; S H Zigmond; E Schiffmann; S Aswanikumar; B Corcoran; E L Becker
Journal:  J Exp Med       Date:  1976-05-01       Impact factor: 14.307

10.  THE ROLE OF SERUM COMPLEMENT IN CHEMOTAXIS OF LEUKOCYTES IN VITRO.

Authors:  P A WARD; C G COCHRANE; H J MUELLER-EBERHARD
Journal:  J Exp Med       Date:  1965-08-01       Impact factor: 14.307

View more
  34 in total

1.  Mechanism of prostaglandin E2 inhibition of acute changes in vascular permeability.

Authors:  K R McLeish; S R Wellhausen; G T Stelzer
Journal:  Inflammation       Date:  1987-09       Impact factor: 4.092

2.  Proteolytic enzymes and arachidonic acid metabolites produced by MRC-5 cells on various microcarrier substrates.

Authors:  J Varani; J D Hasday; R G Sitrin; P G Brubaker; W A Hillegas
Journal:  In Vitro Cell Dev Biol       Date:  1986-10

3.  Inhibition of bleomycin-induced pulmonary fibrosis by nordihydroguaiaretic acid. The role of alveolar macrophage activation and mediator production.

Authors:  S H Phan; S L Kunkel
Journal:  Am J Pathol       Date:  1986-08       Impact factor: 4.307

4.  Prostaglandin E1 suppresses macrophage infiltration and ameliorates injury in an experimental model of macrophage-dependent glomerulonephritis.

Authors:  V Cattell; J Smith; H T Cook
Journal:  Clin Exp Immunol       Date:  1990-02       Impact factor: 4.330

5.  Endotoxin tolerance diminishes certain antiinflammatory effects of endotoxin.

Authors:  J T Rosenbaum; K T Hartiala; E L Howes; I M Goldstein
Journal:  Inflammation       Date:  1985-09       Impact factor: 4.092

6.  Stimulus specificity of prostaglandin inhibition of rabbit polymorphonuclear leukocyte lysosomal enzyme release and superoxide anion production.

Authors:  J C Fantone; W A Marasco; L J Elgas; P A Ward
Journal:  Am J Pathol       Date:  1984-04       Impact factor: 4.307

7.  Role of lipoxygenase products in murine pulmonary granuloma formation.

Authors:  S L Kunkel; S W Chensue; C Mouton; G I Higashi
Journal:  J Clin Invest       Date:  1984-08       Impact factor: 14.808

8.  Polymorphonuclear leukocyte-dependent plasma leakage in the rabbit skin is enhanced or inhibited by prostacyclin, depending on the route of administration.

Authors:  M Rampart; T J Williams
Journal:  Am J Pathol       Date:  1986-07       Impact factor: 4.307

9.  E-type prostaglandins enhance local oedema formation and neutrophil accumulation but suppress eosinophil accumulation in guinea-pig skin.

Authors:  M M Teixeira; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1993-09       Impact factor: 8.739

10.  Plasma prostaglandin E2 concentrations after single dose administration of ketorolac tromethamine (Toradol) in dogs.

Authors:  K Pasloske; J Burger; P Conlon
Journal:  Can J Vet Res       Date:  1998-07       Impact factor: 1.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.